Cinfa – A comprehensive commitment to diabetes
Scientific Progress, Knowledge Exchange, and Continuous Dialogue
Diabetes has become one of the most pressing health challenges worldwide, with the MENA region standing at the epicenter.
According to recent data, this region reports the highest global prevalence—17.6% of adults live with diabetes, and the number of cases is projected to nearly double by 2050, reaching 163 million.
Notably, one in three cases remains undiagnosed, leaving millions at risk of severe complications due to late detection.1
Expanding Access to Quality Therapies
In response, Cinfa, the leading laboratory in the Spanish pharmaceutical market and with presence in over 100 countries worldwide, is reinforcing its dedication to improving chronic disease care in the Gulf, building on a strategy that has been implemented for over 10 years, focusing on chronic diseases such as diabetes and cardiovascular conditions.
The company combines pharmaceutical advances with targeted therapeutic development to provide effective treatment options, while fostering scientific collaboration to better understand regional healthcare challenges.
Building on these insights and in line with its commitment to providing effective solutions for type 2 diabetes, Cinfa works to optimize blood glucose regulation.
In this context, the company has introduced vildagliptin, under the brand name Gliptacin, for the treatment of type 2 diabetes.
It can be used as monotherapy – in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance – and as combination therapy as well.
In the coming months, this therapy will also be available in combination with metformin, under the brand name Gliptacin Met, providing an additional option for comprehensive diabetes management.
“We have a responsibility to improve global access to the highest-quality treatments, and this is a core part of our mission—especially when it comes to highly prevalent conditions such as diabetes” emphasized Dr. Alicia López de Ocáriz, Corporate Medical Director at Cinfa Group.
Dr. López de Ocáriz, Corporate Medical Director at Cinfa Group, stressed the importance of ensuring global access to high-quality treatments, highlighting that this requires continued R&D investment, accessibility, adherence support, and prevention programs.
With 56 years of experience and a team of over 2,300 professionals, Cinfa provides accessible and quality pharmaceutical solutions, merging expertise, innovation, and a strong commitment to global well-being.
Strengthening Scientific Collaboration
Cinfa approaches diabetes care as part of a broad, sustained effort involving multiple disciplines, andpromoting continuous scientific dialogue and knowledge exchange through events and training programs.
This approach underlines the importance of interdisciplinary collaboration, ongoing medical education, and incorporating patient experiences to inform clinical decisions and improve long-term outcomes.
Beyond therapeutic solutions, Cinfa actively participates in leading scientific congresses across the Middle East, strengthening partnerships with regional and international experts and reinforcing a long-term vision of collaboration to improve patient care.
As part of this commitment and given that cardiovascular diseases are the main complications of diabetes, Cinfa continues to actively engage in initiatives that foster closer collaboration with healthcare professionals, exemplified by its participation for the third consecutive year in the 36th Annual Conference of the Saudi Heart Association (SHA 2025).
The company has shown its cardiovascular portfolio to healthcare professionals, demonstrating its ongoing commitment to providing accessible, high-quality, evidence-based therapies aimed at improving patient outcomes across the Middle East.
By joining this international gathering, Cinfa contributes to the scientific exchange, driving advances in cardiovascular medicine and reinforcing its dedication to sustainable, patient-focused healthcare systems.
Cinfa is the leading laboratory in units and values in the Spanish pharmaceutical market, present in over 100 countries.
References
Be the first to leave a comment